CTRI/2024/02/062290尚未招募Unknown
Comparison of Efficacy of Inhaled Formoterol and Budesonide Combination versus Budesonide Monotherapy in Children Aged 6 to 18 years with Bronchial Asthma in Improving Disease Control and Quality of Life: A Randomized Controlled Trial - FORM-BUD
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Children aged 6-18 years
- •2. Bronchial asthma requiring treatment as per GINA guidelines step 1 to 4
- •3. Ability to perform spirometry in accordance with the standards of the American
- •Thoracic Society
排除标准
- •1. Co-existent other chronic pulmonary diseases
- •2. Chronic renal, gastrointestinal diseases, hepatic or cardiac diseases
- •3. History of active smoking
- •4. Patient who took a systemic corticosteroid within the previous 4 weeks
- •5. Prior PICU admission for asthma
研究者
相似试验
已完成
不适用
Efficacy of formoterol inhalation in patients with chronic obstructive pulmonary disease: investigation of the effects on the central and peripheral airways starting from immediately after inhalatioChronic obstructive pulmonary disease (COPD)JPRN-UMIN000013318General incorporated association, Academy of Inhalation Methods (AIMs)60
尚未招募
1 期
Comparison of two inhalers in cases of COPDCTRI/2023/07/054973SHRI BM PATIL MEDICAL COLLEGE
已完成
4 期
Efficacy of Formoterol vs Ipatropioum Bromide Plus Fenoterol in Children (5-<12 Years) With Acute Bronchial ObstructionAcute Bronchial Obstruction, AsthmaNCT00460577Novartis60
已完成
3 期
Effect of Formoterol in treatment of covid19Condition 1: corona virus or COVID-19. Condition 2: COVID 19 ,virus not identified.COVID-19, virus identifiedCOVID-19, virus not identifiedU07.1U07.2IRCT20170210032478N3ational Research Institute of Tuberculosis and Lung Diseases200
已完成
不适用
Study on the effects of the budesonide/formoterol combination formulation in improving airway inflammation and airway resistance in patients with bronchial asthmaPatients with bronchial asthma aged 20 years and older (males and females, outpatients and inpatients) being treated with an ICS (at a dose equivalent to FP 200-1000 mcg/day) and salmeterol 100 mcg/day in combination (either as two separate products or one combined product) for 3 months or longer with poor or inadequate controlJPRN-UMIN000006572Chiba-Hokusoh Hospital, Nippon Medical School80